Get started
Taysha Gene Therapies, Inc.Taysha Gene Therapies, Inc.Taysha Gene Therapies, Inc.

Taysha Gene Therapies, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

TSHA chart


Full chart

TSHA upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪358.65 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.03 USD
Net income (FY)
‪−111.57 M‬ USD
Revenue (FY)
‪15.45 M‬ USD
Shares float
‪153.61 M‬
Beta (1Y)
2.68

Employees


Employees (FY)
52
Change (1Y)
−13 −20.00%
Revenue / Employee (1Y)
‪297.13 K‬ USD
Net income / Employee (1Y)
‪−2.15 M‬ USD

About Taysha Gene Therapies, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Sean P. Nolan
Website
tayshagtx.com
Headquarters
Dallas
Founded
2019
FIGI
BBG00TJXFDP1
Taysha Gene Therapies, Inc.is a patient-centric, clinical-stage gene therapy company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing. The company was founded by Steven Gray, Berge Minassian, and R. A. Session II in 2019 and is headquartered in Dallas, TX.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

TSHA news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of TSHA is 1.73 USD — it has decreased by −3.71% in the past 24 hours. Watch Taysha Gene Therapies, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Taysha Gene Therapies, Inc. stocks are traded under the ticker TSHA.
TSHA stock has fallen by −7.92% compared to the previous week, the month change is a −44.02% fall, over the last year Taysha Gene Therapies, Inc. has showed a −4.42% decrease.
We've gathered analysts' opinions on Taysha Gene Therapies, Inc. future price: according to them, TSHA price has a max estimate of 8.00 USD and a min estimate of 5.00 USD. Watch TSHA chart and read a more detailed Taysha Gene Therapies, Inc. stock forecast: see what analysts think of Taysha Gene Therapies, Inc. and suggest that you do with its stocks.
TSHA reached its all-time high on Jan 19, 2021 with the price of 33.35 USD, and its all-time low was 0.50 USD and was reached on Jun 26, 2023. View more price dynamics on TSHA chart.
See other stocks reaching their highest and lowest prices.
TSHA stock is 6.34% volatile and has beta coefficient of 2.68. Track Taysha Gene Therapies, Inc. stock price on the chart and check out the list of the most volatile stocks — is Taysha Gene Therapies, Inc. there?
Today Taysha Gene Therapies, Inc. has the market capitalization of ‪358.65 M‬, it has increased by 1.09% over the last week.
Yes, you can track Taysha Gene Therapies, Inc. financials in yearly and quarterly reports right on TradingView.
Taysha Gene Therapies, Inc. is going to release the next earnings report on Mar 26, 2025. Keep track of upcoming events with our Earnings Calendar.
TSHA earnings for the last quarter are −0.10 USD per share, whereas the estimation was −0.09 USD resulting in a −15.31% surprise. The estimated earnings for the next quarter are −0.08 USD per share. See more details about Taysha Gene Therapies, Inc. earnings.
Taysha Gene Therapies, Inc. revenue for the last quarter amounts to ‪1.79 M‬ USD, despite the estimated figure of ‪1.74 M‬ USD. In the next quarter, revenue is expected to reach ‪2.14 M‬ USD.
TSHA net income for the last quarter is ‪−25.52 M‬ USD, while the quarter before that showed ‪−20.93 M‬ USD of net income which accounts for −21.96% change. Track more Taysha Gene Therapies, Inc. financial stats to get the full picture.
No, TSHA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 30, 2024, the company has 52.00 employees. See our rating of the largest employees — is Taysha Gene Therapies, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Taysha Gene Therapies, Inc. EBITDA is ‪−81.19 M‬ USD, and current EBITDA margin is −453.06%. See more stats in Taysha Gene Therapies, Inc. financial statements.
Like other stocks, TSHA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Taysha Gene Therapies, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Taysha Gene Therapies, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Taysha Gene Therapies, Inc. stock shows the sell signal. See more of Taysha Gene Therapies, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.